Related Experiment Video
Updated: Jan 24, 2026

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools
Published on: June 20, 2020
Age Does Not Affect Respiratory Characteristics in Children With Prader-Willi Syndrome Before and After Growth
Michelle Ip1, Sze Lut Cheng1, Okkes R Patoglu1
1Department of Paediatrics, Monash University, Melbourne, Australia.
Insights
Children with Prader-Willi syndrome (PWS) treated with growth hormone do not show increased risk for sleep apnea. Very young children (<2 years) and older children (≥2 years) had similar outcomes for obstructive sleep apnea (OSA) and central sleep apnea (CSA).
Area of Science:
- Pediatric Endocrinology
- Sleep Medicine
- Genetics
Background:
- Prader-Willi syndrome (PWS) is associated with increased risks of central sleep apnea (CSA) and obstructive sleep apnea (OSA).
- Growth hormone (GH) therapy is often initiated in young children with PWS before age 2.
- Previous studies on GH effects on sleep apnea in PWS have focused on older children.
Purpose of the Study:
- To evaluate the impact of age on the prevalence of OSA and CSA in children with PWS.
- To analyze sleep and respiratory characteristics in relation to age.
- To determine the effects of growth hormone therapy on OSA and CSA in different age groups.
Main Methods:
- Retrospective review of polysomnography data from children with PWS.
- Data collected pre- and post-growth hormone treatment between January 2011 and June 2024.
- Comparison of sleep apnea metrics between children younger than 2 years and those 2 years or older.
Main Results:
- Pre-GH therapy, children aged ≥2 years had more severe OSA than those <2 years (p<0.05); no age difference in CSA severity.
- Post-GH therapy, OSA developed in 21% of children <2 years and 20% of children ≥2 years.
- CSA resolved in 21% (<2 years) and 6% (≥2 years), while new-onset CSA occurred in 11% (<2 years) and 13% (≥2 years).
Conclusions:
- Growth hormone therapy does not appear to increase the risk of developing OSA or CSA in very young children with PWS.
- Age does not significantly influence the development or resolution of sleep apnea following growth hormone treatment in PWS.
- These findings support the safety of initiating growth hormone therapy early in children with PWS regarding sleep apnea risks.
Aim:
Children with Prader-Willi syndrome (PWS) are at increased risk of both central (CSA) and obstructive sleep apnoea (OSA). Studies examining the effects of growth hormone have focused on older children; however, therapy is often initiated before the age of 2 years. We determined the effects of age on (1) the number of children diagnosed with OSA and CSA; (2) the sleep and respiratory characteristics and (3) the effects of growth hormone on OSA and CSA.
Methods:
Retrospective review of children with PWS who underwent polysomnography pre- and post-growth hormone between January 2011 and June 2024.
Results:
Fifty-six children (35 < 2 years; 21 ≥ 2 years) pre-growth hormone; 28 children < 2 years and 15 children ≥ 2 years after growth hormone. Pre-growth hormone, children ≥ 2 years had more severe OSA than children < 2 years (p < 0.05). There was no difference between age groups for CSA. Post-growth hormone, 21% of children < 2 years and 20% of children ≥ 2 years developed OSA. CSA resolved post-growth hormone in 21% of children < 2 years and 6% of children ≥ 2 years, whilst CSA developed in 11% and 13%, respectively.
Conclusion:
Our study highlights that very young children do not appear to be at higher risk of development of OSA or CSA when treated with growth hormone.
Related Concept Videos
Plant Hormones
Types of Hormones
Hormonal Regulation
Hormonal Regulation
Characteristics of Life
Role of Affect in Interpersonal Attraction

